URGN News & Analysis
5 articles
Market Mood
UroGen Pharma (URGN) Rating Maintained After FDA Filing Acceptance
H.C. Wainwright has reiterated its stock rating for UroGen Pharma (URGN) following the acceptance of a recent FDA filing. The article focuses on the firm's maintained stance without providing new financial figures or detailed guidance updates. The acceptance of the FDA filing is a significant regulatory milestone for UroGen Pharma. However, no specific data on the filing’s content or timing was provided. The analyst firm’s decision to maintain its rating suggests confidence in the company's regulatory progress without altering outlooks at this stage. This event matters because FDA filing acceptances often precede important decisions that may affect future revenues and product availability. Investors in UroGen Pharma should note this regulatory confirmation as a positive procedural step but await further data or results to gauge impact on stock value.
Read More: UroGen Pharma (URGN) Rating Maintained After FDA Filing Acceptance
UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer
Oppenheimer has increased the price target of UroGen Pharma (URGN) to $50, driven by positive sales outlook. This adjustment reflects expectations for future revenue growth and potential market performance. The revised target indicates increased confidence in UroGen's business trajectory. This news is significant for investors as it may influence stock performance and investor sentiment toward UroGen Pharma.
Read More: UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer
UroGen Pharma (URGN) CMO Sells 5,222 Shares for $143,000
Mark Schoenberg, CMO of UroGen Pharma Ltd. (URGN), sold 5,222 shares for approximately $143,000, as reported in a SEC Form 4 filing. Following the transaction, his direct ownership consists of 139,763 shares valued at about $3.81 million. This sale represents a 25.81% decrease in Schoenberg's direct holdings over the past year, where he has completed seven sell transactions. The shares were sold at a weighted average price of $27.30 amid a 168.23% one-year total return as of June 12, 2026.
Read More: UroGen Pharma (URGN) CMO Sells 5,222 Shares for $143,000
UroGen Pharma Ltd. (URGN) Form 144 Filed on June 9
UroGen Pharma Ltd. (URGN) filed Form 144 on June 9 for potential transactions involving the sale of shares by insiders. This filing allows for the sale of shares under specific restrictions, which could influence the stock's liquidity. The current trading volume and any changes in share ownership following this filing are relevant for investor sentiment. Monitoring such regulatory filings helps investors gauge potential stock movements and insider activity.
Read More: UroGen Pharma Ltd. (URGN) Form 144 Filed on June 9
UroGen Pharma (URGN) Q1 2026 EPS Beats Expectations by 10%
UroGen Pharma (URGN) reported its Q1 2026 earnings, exceeding EPS forecasts by 10%. The company's actual EPS was $1.10, compared to the anticipated $1.00. This performance is significant as it reflects UroGen's strong financial position and market confidence. Such earnings reports often influence investor sentiment and can lead to increased trading volumes in the stock. Analysts are closely watching URGN's future performance to gauge market trends.
Read More: UroGen Pharma (URGN) Q1 2026 EPS Beats Expectations by 10%